Look-back screening for the identification of transfusion-induced hepatitis C virus infection in Sweden

Scandinavian Journal of Infectious Diseases

Volumn 43, Issue 6-7, 2011, Pages 522-527

  Ydreborg, Magdalena ^a   Söderström, Ann ^b   Håkanson, Agneta ^a   Alsiö, Åsa ^c   Arnholm, Birgitta ^d   Malmström, Petter ^e   Hellstrand, Kristoffer ^a   Westin, Johan ^a   Lagging, Martin ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Department of Communicable Disease Control ^*  (Sweden)

^c Skovde Hospital   (Sweden)

^d Section of Hematology   (Sweden)

^e Northern Alvsborg Hospital   (Sweden)

Author keywords

antiviral treatment; blood transfusion; Hepatitis C virus; liver fibrosis and prevalence

Indexed keywords

RNA;

ADULT; AGED; ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; CHILDBIRTH; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE;

ADULT; AGED; BLOOD TRANSFUSION; FEMALE; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; SEROLOGIC TESTS; SWEDEN;

EID: 79959281087     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2011.562526     Document Type: Article

References (23)

1. Norda R, Duberg AS, Sonnerborg A, Olcen P. Transmission of hepatitis C virus by transfusion in Orebro County, Sweden, 1990-1992. Scand J Infect Dis 1995;27:449-52.
2. Foberg U, Ekermo B, Widell A, Mathiesen U, Fryden A. Hepatitis C virus transmission, 1988-1991, via blood components from donors subsequently found to be anti-HCVpositive. Scand J Infect Dis 1996;28:21-6.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
4. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;-347:975-82.
5. Socialstyrelsen. Rekommendation för screening av patientgrupper som fått blodtransfusion i Sverige före 1992 (National Board of Health and Welfare. Recommendation for screening of patients who received blood transfusion prior to 1992). Sweden: National Board of Health and Welfare; 2007. Available at: http://www.socialstyrelsen.se/publikationer2007/2007-130-6 (Accessed 20 August 2008).
6. Engholm A. Smittat blod blev Marias död (Contagious blood caused Maria's death). Göteborgs Posten, 19 May 2007.
7. Lindh M, Hannoun C. Genotyping of hepatitis C virus by TaqMan real-time PCR. J Clin Virol 2005;34:108-14. (Pubitemid 41278610)
8. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867-72. (Pubitemid 40978865)
9. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-17.
10. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93. (Pubitemid 26260021)
11. Lidgren M, Hollander A, Weiland O, Jonsson B. Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of life. Scand J Gastroenterol 2007;42:867-77. (Pubitemid 46897621)
12. Wahl M, Hermodsson S, Leman J, Lindholm A, Wejstål R, Norkrans G. Prevalence of antibodies against hepatitis B and C among pregnant women and female blood donors in Sweden. Serodiagn Immunother Infect Dis 1994;6:127-9. (Pubitemid 24287574)
13. Duberg AS, Nordstrom M, Torner A, Reichard O, Strauss R, Janzon R, et al. Non-Hodgkin's lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005;41:652-9. (Pubitemid 40289514)
14. Tynell E, Norda R, Shanwell A, Bjorkman A. Long-term survival in transfusion recipients in Sweden, 1993. Transfusion 2001;41:251-5.
15. Smittskyddsinstitutet. Statistik hepatit C (Swedish Institute for Infectious Disease Control. Hepatitis C statistics). Sweden, 2010: Smittskyddsinstitutet; Available at: http://www.smittskyddsinstitutet.se/ statistik/hepatit-c/ (Accessed 17 January 2010).
16. Davoren A, Dillon AD, Power JP, Donnellan J, Quinn JM, Willis JW, et al. Outcome of an optional HCV screening program for blood transfusion recipients in Ireland. Transfusion 2002;42:1501-6.
17. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-32. (Pubitemid 27129209)
18. Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991;14:969-74.
19. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology 1998;28:562-7. (Pubitemid 28363687)
20. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33. (Pubitemid 29181642)
21. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype 1b) singlesource outbreak in Germany: a 20-year multicenter study. Hepatology 2000;32:91-6. (Pubitemid 30432371)
22. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the mpleentation of blood-donor screening. N Engl J Med 1999;341:866-70. (Pubitemid 29427048)
23. Engholm A. En månad efter beskedet var Ingrid död (Ingrid died one month after being informed). Göteborgs Posten, 7 January 2008.